| Literature DB >> 35923645 |
Mitsuyo Kawaguchiya1, Noriko Urushibara1, Meiji Soe Aung1, Shigeki Shimada2, Mayumi Nakamura3, Masahiko Ito3, Satoshi Habadera3, Nobumichi Kobayashi1.
Abstract
Objectives: This study aimed to elucidate the molecular characteristics and antimicrobial resistance of Streptococcus agalactiae (group B streptococcus, GBS) colonizing pregnant women in Japan.Entities:
Keywords: CC, clonal complex; GBS, group B streptococcus; Japan; MICs, minimum inhibitory concentrations; MLST, multilocus sequence typing; QRDRs, quinolone resistance-determining regions; Quinolone resistance; ST, sequence type; Sequence type; Serotype; Streptococcus agalactiae
Year: 2022 PMID: 35923645 PMCID: PMC9340534 DOI: 10.1016/j.ijregi.2022.07.002
Source DB: PubMed Journal: IJID Reg ISSN: 2772-7076
Distribution of capsular serotypes and clonal complexes (CCs)/sequence types (STs) for 76 GBS isolates.
| Clonal complex | Sequence type | Total no. | Number of isolates (% in each ST) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (CC) | (ST) | (%) | Capsuler serotype | |||||||
| (no. of isolates) | Ia | Ib | II | III | IV | V | VI | VIII | ||
| CC1 (23) | ST1 | 12 (15.8) | 0 | 0 | 1 (8.3) | 1 (8.3) | 0 | 7 (58.3) | 2 (16.7) | 1 (8.3) |
| ST196 | 4 (5.3) | 0 | 0 | 0 | 0 | 4 (100) | 0 | 0 | 0 | |
| ST676 | 4 (5.3) | 0 | 0 | 4 (100) | 0 | 0 | 0 | 0 | 0 | |
| ST3 | 2 (2.6) | 0 | 2 (100) | 0 | 0 | 0 | 0 | 0 | 0 | |
| ST2 | 1 (1.3) | 0 | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | |
| CC19 (20) | ST335 | 10 (13.2) | 0 | 0 | 0 | 10 (100) | 0 | 0 | 0 | 0 |
| ST19 | 6 (7.9) | 0 | 0 | 3 (50.0) | 0 | 0 | 3 (50.0) | 0 | 0 | |
| ST27 | 2 (2.6) | 0 | 0 | 0 | 2 (100) | 0 | 0 | 0 | 0 | |
| ST131 | 1 (1.3) | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 | |
| ST324 | 1 (1.3) | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 | |
| CC23 (14) | ST23 | 9 (11.8) | 8 (88.9) | 0 | 0 | 0 | 0 | 1 (11.1) | 0 | 0 |
| ST144 | 3 (3.9) | 3 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ST88 | 1 (1.3) | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ST199 | 1 (1.3) | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CC17 (7) | ST17 | 7 (9.2) | 0 | 0 | 0 | 7 (100) | 0 | 0 | 0 | 0 |
| CC10 (6) | ST10 | 3 (3.9) | 0 | 3 (100) | 0 | 0 | 0 | 0 | 0 | 0 |
| ST1410 | 2 (2.6) | 0 | 2 (100) | 0 | 0 | 0 | 0 | 0 | 0 | |
| ST752 | 1 (1.3) | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | |
| CC452 (3) | ST452 | 3 (3.9) | 0 | 0 | 0 | 0 | 3 (100) | 0 | 0 | 0 |
| CC26 (1) | ST26 | 1 (1.3) | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 |
| CC529 (1) | ST529 | 1 (1.3) | 0 | 0 | 0 | 1 (100) | 0 | 0 | 0 | 0 |
| CC1524 (1) | ST1524 | 1 (1.3) | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 |
| Total no. (%) | 76 (100) | 13 (17.1) | 8 (10.5) | 6 (7.9) | 24 (31.6) | 7 (9.2) | 15 (19.7) | 2 (2.6) | 1 (1.3) | |
Antimicrobial susceptibility of 76 GBS isolates belonging to different capsular serotypes recovered from pregnant women.
| Antimicrobial agent | Percentage of intermediate resistance (I) and resistance (R), and (I/R) in each capsuler serotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ia | Ib | II | III | IV | V | VI | VIII | Total | |
| (n=13) | (n=8) | (n=6) | (n=24) | (n=7) | (n=15) | (n=2) | (n=1) | (n=76) | |
| I+R (I/R) | I+R (I/R) | I+R (I/R) | I+R (I/R) | I+R (I/R) | I+R (I/R) | I+R (I/R) | I+R (I/R) | I+R (I/R) | |
| Erythromycin | 23.1 (0/23.1) | 37.5 (0/37.5) | 33.3 (0/33.3) | 41.6 (8.3/33.3) | 42.9 (0/42.9) | 60.0 (6.7/53.3) | 50.0 (0/50.0) | 0 | 40.7 (3.9/36.8) |
| Azithromycin | 23.1 (0/23.1) | 50.0 (12.5/37.5) | 33.3 (0/33.3) | 70.8 (0/70.8) | 42.9 (0/42.9) | 60.0 (0/60.0) | 50.0 (0/50.0) | 0 | 51.3 (1.3/50.0) |
| Clarithromycin | 30.8 (0/30.8) | 37.5 (0/37.5) | 33.3 (0/33.3) | 66.7 (25.0/41.7) | 42.9 (0/42.9) | 60.0 (0/60.0) | 50.0 (0/50.0) | 0 | 50.0 (7.9/42.1) |
| Clindamycin | 15.4 (7.7/7.7) | 50.0 (12.5/37.5) | 0 | 37.5 (0/37.5) | 42.9 (0/42.9) | 40.0 (0/40.0) | 50.0 (0/50.0) | 0 | 34.2 (3.9/30.3) |
| Levofloxacin | 0 | 87.5 (0/87.5) | 0 | 4.2 (0/4.2) | 0 | 26.7 (0/26.7) | 0 | 0 | 15.8 (0/15.8) |
All isolates were susceptible to penicillin, ampicillin, imipenem, meropenem, cefotaxime, and vancomycin (data not shown).